Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 4, randomized, open-label, comparative, multicenter study to assess the safety and efficacy of induction agents, alemtuzumab, basiliximab or rabbit anti-thymocyte globulin in combination with tacrolimus, MMF, and a rapid steroid withdrawal in renal transplant recipients.

X
Trial Profile

Phase 4, randomized, open-label, comparative, multicenter study to assess the safety and efficacy of induction agents, alemtuzumab, basiliximab or rabbit anti-thymocyte globulin in combination with tacrolimus, MMF, and a rapid steroid withdrawal in renal transplant recipients.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Antithymocyte globulin (Primary) ; Basiliximab (Primary) ; Mycophenolate mofetil; Steroids; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms INTAC
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 19 May 2011 Results published in the New England Journal of Medicine.
    • 19 Aug 2010 Final 36-month results presented at the 23rd International Congress of the Transplantation Society.
    • 02 Jun 2010 Final 36-month results presented at the American Transplant Congress -- 10th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top